3 Things In Biotech, May 26: Immunotherapy Strikes Lung Cancer Yet Again


Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. News: AZN announced that the phase 3 PACIFIC trial has met its second primary endpoint, overall survival.



from Biotech News